Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best healthcare stocks to buy with highest upside potential.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on May 28 that maftivimab has been recommended by the World Health Organization’s (WHO) Therapeutics Advisory Group to be prioritized for evaluation in clinical trials of investigational treatments for Bundibugyo ebolavirus
Maftivimab is the most potent neutralizing antibody included in Inmazeb®, according to the company, and has exhibited broad activity in vitro against multiple Ebola species, including Bundibugyo. Management further reported that the trial relates to the recent declaration by the WHO that the current outbreak of Ebola disease caused by Bundibugyo virus in Uganda and the Democratic Republic of the Congo (DRC) constitutes a public health emergency of international concern. In another development, Canaccord cut the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $875 from $1,057 on May 19, maintaining a Buy rating on the shares.
The firm updated its model on the stock after its Phase 3 study of fianlimab+cemiplimab vs pembrolizumab failed to hit statistical significance on the primary endpoint of progression-free survival (PFS), which it considered a surprising and disappointing event. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a pharmaceutical company that develops, discovers, and commercializes therapies for several diseases, including cancer, eye disorders, and allergic conditions. While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.